Pharmacogenetics, pharmacogenomics, and individualized medicine (Q23919667)

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Digoxin pharmacokinetics and MDR1 genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Association of warfarin dose with genes involved in its action and metabolism

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenetic perspectives gained from twin and family studies

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenetics and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Origins of individual variability in P4501A induction

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Medical genetics: a marker for Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Targeted cancer therapies in the twenty-first century: lessons from imatinib

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Identification of the gene for vitamin K epoxide reductase

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Moving towards individualized medicine with pharmacogenomics

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

HLA-B*5701 screening for hypersensitivity to abacavir

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Inheritance and drug response

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics--drug disposition, drug targets, and side effects

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

A common polymorphism associated with antibiotic-induced cardiac arrhythmia

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics of 4-hydroxycoumarin anticoagulants

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2)

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Some statistical data on atypical cholinesterase of human serum

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Apixaban metabolism and pharmacokinetics after oral administration to humans

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Personalized medicine, pharmacogenetics, and clopidogrel: unraveling variability of response.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Richard Weinshilboum: Pharmacogenetics: The future is here!

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

The pharmocogenomics of warfarin: closing in on personalized medicine

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Genetic control of isoniazid metabolism in man

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics and individualized drug therapy

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics: unlocking the human genome for better drug therapy

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Interindividual variability in inhibition and induction of cytochrome P450 enzymes

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Translation of the Philadelphia chromosome into therapy for CML.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients.

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Genetic testing for warfarin dosing? Not yet ready for prime time

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Warfarin pharmacogenetics

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Clinical pharmacogenetics and potential application in personalized medicine

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021

Pharmacogenomics: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1124%2FPR.110.003533

7 January 2021